Innovation in Arabic online newsrooms: by Abdel-Sattar, N

Screening for diabetes in patients with cardiovascular disease: HbA1c trumps oral glucose tolerance testing by Preiss, D, Sattar, N

Reverse causality in cardiovascular epidemiological research. More common than imagined? by Sattar, N, Preiss, D

Research digest: CV trials in diabetes — Looking ahead by Preiss, D, Sattar, N

Diabetic microvascular complications as simple indicators of risk for cardiovascular outcomes and heart failure by Preiss, D, Sattar, N

Metformin therapy and circulating NT-proBNP levels: the CAMERA trial by Preiss, D, Welsh, P, Sattar, N

Plasma fatty acids and the risk of vascular and mortality outcomes in individuals with type 2 diabetes: results from the ADVANCE study by Harris, K, Oshima, M, Sattar, N, Mark Woodward

Applying metabolomics to cardiometabolic intervention studies and trials: past experiences and a roadmap for the future. by Rankin, N, Preiss, D, Welsh, P, Sattar, N

Associations of targeted circulating microRNAs with insulin resistance in the CAMERA (Carotid Atherosclerosis: MEtformin for insulin ResistAnce) trial by Alramah, T, Preiss, D, Sattar, N, Logue, J, Welsh, P

Patients with a range of rheumatic diseases are at increased risk of cardiovascular disorders towards a re-evaluation of the European League against Rheumatism (EULAR)’s recommenda... by Conrad, N, McInnes, IB, Mcmurray, JJV, Sattar, N

Putative miRNA biomarkers of insulin resistance and the effect of metformin: data from the CAMERA trial by ALRamah, T, Pinel, K, Preiss, D, Sattar, N, Logue, J, Welsh, P

SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms? by Sattar, N, McLaren, J, Kristensen, S, Preiss, D, McMurray, J

A multicenter, randomized, placebo‐controlled trial of atorvastatin for the primary prevention of cardiovascular events in patients with rheumatoid arthritis by Kitas, G, Nightingale, P, Armitage, J, Sattar, N, Belch, J, Symmons, D

Medical Research Council Hot Topic workshop report: Planning a UK Nutrition and Healthy Life Expectancy Trial by Carter, J, Mathers, J, Fairweather‐Tait, S, Jebb, S, Sattar, N, Jennings, A, Minihane, A

The potential for a two-stage diabetes risk algorithm combining non-laboratory-based scores with subsequent routine non-fasting blood tests: results from prospective studies in old... by Wannamethee, S, Papacosta, O, Whincup, P, Thomas, M, Carson, C, Lawlor, D, Ebrahim, S, Sattar, N

Risk of anaemia with long-term metformin use in a community setting by Donnelly, L, Gardner, K, Coleman, R, Sattar, N, Hattersley, A, Holman, R, Pearson, E

Body-mass index, abdominal adiposity, and cardiovascular risk Reply by Wormser, D, Di Angelantonio, E, Sattar, N, Collins, R, Thompson, S, Danesh, J, Collaboratio, E

Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data by Sattar, N, Preiss, D, Robinson, J, Djedjos, C, Elliott, M, Somaratne, R, Wasserman, S, Raal, F

A COMPARATIVE STUDY OF PROXIMATE COMPOSITION OF ARTEMIA URMIANA ENRICHED WITH DIFFERENT SOURCES by M. Hafezieh; S. Kamarodin; Ch. Roz ben sad; M. Kamal abd sattar; N. Agh; H. Hossein por

Get full text

Long-term efficacy of evolocumab in reducing lipids in EU subjects with and without type 2 diabetes: an analysis from the open-label extension OSLER studies by Sattar, N, Valensi, P, Preiss, D, Dent, R, Bridges, I, Ruzza, A, Cyrille, M, Handelsman, Y